BRAIN.Q

Restorative Brain Health Therapeutics to Reverse Disability After Neurological Disease

Health Tech & Life Sciences
Active
Series B Jerusalem, Israel Founded 2016
Last updated 2026-06-18
Total raised
$52.4M
Last: 2021-08
Stage
Series B
Founded
2016
Headcount
35
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

BRAIN.Q is redefining the future of neurological recovery, with a mission to transform lives through innovative, noninvasive therapies. The company utilizes advanced AI-powered technology to develop network-targeting electromagnetic precision therapy, designed to enhance and accelerate brain recovery following ischemic stroke—the leading cause of disability worldwide. Delivered through a cloud-based platform, the therapy is seamlessly adaptable for both hospital and home settings.

Celebrated as a pioneer in neurological innovation, BRAIN.Q has earned CE Mark approval, the FDA’s Breakthrough Device Designation, and the esteemed recognition of the European Innovation Council.

Building on these advancements, BRAIN.Q is actively progressing its pivotal EMAGINE II study in the U.S., aiming to secure FDA clearance for its Q Therapeutic System and expand its transformative impact on patient recovery.

Guided by a world-class leadership team and a bold vision for the future of neurological recovery, BRAIN.Q is driven by its mission to restore brain health and dignity to stroke survivors, empowering them to regain independence.

Funding history · 4 rounds · $52.4M total

Q&A

What is BRAIN.Q's primary focus?
BRAIN.Q is focused on restorative brain health therapeutics to reverse disability after neurological disease, specifically developing AI-powered electromagnetic precision therapy for brain recovery following ischemic stroke.
When was BRAIN.Q founded?
BRAIN.Q was founded in August 2016.
What is the current employee count for BRAIN.Q?
BRAIN.Q has 35 employees, falling within the 11-50 employee bucket.
What is the total amount of funding BRAIN.Q has raised to date?
BRAIN.Q has raised a total of $52,400,000 in funding.
Which investors participated in BRAIN.Q's August 2021 funding round?
In August 2021, BRAIN.Q raised $39,000,000 with lead investors Hanaco Ventures and OurCrowd.
What significant regulatory designations has BRAIN.Q received?
BRAIN.Q has earned CE Mark approval and the FDA’s Breakthrough Device Designation.
What is BRAIN.Q currently working on in the U.S.?
BRAIN.Q is actively progressing its pivotal EMAGINE II study in the U.S., aiming to secure FDA clearance for its Q Therapeutic System.
Where are BRAIN.Q's main offices located?
BRAIN.Q's headquarters are in Jerusalem, Israel, with an additional office in Englewood Cliffs, NJ, USA.

Team · 3

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder & CSO
LinkedIn ↗
Founder · Co-founder & Chief Innovation Officer
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Therapeutics
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B2CB2B

Highlights

1 PatentsVerified

Tags

non-invasivestrokedegenerative-diseasesmedical-devicesneurologyrehabilitationartificial-intelligencemachine-learningdigital-healthcareclinicshospitalsmedical-technologiesneurosciencedigital-therapeuticspatientswearablemhealth
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)